Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

Yasuto Yoneshima, Kentaro Tanaka, Yoshimasa Shiraishi, Kojiro Hata, Hiroyuki Watanabe, Taishi Harada, Kohei Otsubo, Eiji Iwama, Hiroyuki Inoue, Satohiro Masuda, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalArticle

Abstract

Objectives: To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small cell lung cancer (NSCLC). Patients and methods: Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor. Results: Of the 83 patients analyzed, 18 (21.7%) were positive for ANA. The incidence of immune-related adverse events (irAEs) did not differ significantly between patients with ANA (6/18, 33.3%) and those negative for ANA (21/65, 32.3%), although it tended to increase as the ANA titer increased. Progression-free survival (2.9 versus 3.8 months, p = 0.03) and overall survival (11.6 versus 15.8 months, p = 0.03) were significantly shorter in patients positive for ANA than in those without ANA. Conclusion: PD-1 inhibitors can be administered safely in advanced NSCLC patients positive for ANA without obvious exacerbation of autoimmune disease, although patients with a high titer of such antibodies may warrant close monitoring. However, the presence of ANA might be associated with a poor outcome of such treatment.

Original languageEnglish
Pages (from-to)5-9
Number of pages5
JournalLung Cancer
Volume130
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Antinuclear Antibodies
Non-Small Cell Lung Carcinoma
Safety
Autoimmune Diseases
Disease-Free Survival
Survival
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies. / Yoneshima, Yasuto; Tanaka, Kentaro; Shiraishi, Yoshimasa; Hata, Kojiro; Watanabe, Hiroyuki; Harada, Taishi; Otsubo, Kohei; Iwama, Eiji; Inoue, Hiroyuki; Masuda, Satohiro; Nakanishi, Yoichi; Okamoto, Isamu.

In: Lung Cancer, Vol. 130, 01.04.2019, p. 5-9.

Research output: Contribution to journalArticle

Yoneshima, Yasuto ; Tanaka, Kentaro ; Shiraishi, Yoshimasa ; Hata, Kojiro ; Watanabe, Hiroyuki ; Harada, Taishi ; Otsubo, Kohei ; Iwama, Eiji ; Inoue, Hiroyuki ; Masuda, Satohiro ; Nakanishi, Yoichi ; Okamoto, Isamu. / Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies. In: Lung Cancer. 2019 ; Vol. 130. pp. 5-9.
@article{bf7061a74cd4407da87e28cf96843dba,
title = "Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies",
abstract = "Objectives: To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small cell lung cancer (NSCLC). Patients and methods: Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor. Results: Of the 83 patients analyzed, 18 (21.7{\%}) were positive for ANA. The incidence of immune-related adverse events (irAEs) did not differ significantly between patients with ANA (6/18, 33.3{\%}) and those negative for ANA (21/65, 32.3{\%}), although it tended to increase as the ANA titer increased. Progression-free survival (2.9 versus 3.8 months, p = 0.03) and overall survival (11.6 versus 15.8 months, p = 0.03) were significantly shorter in patients positive for ANA than in those without ANA. Conclusion: PD-1 inhibitors can be administered safely in advanced NSCLC patients positive for ANA without obvious exacerbation of autoimmune disease, although patients with a high titer of such antibodies may warrant close monitoring. However, the presence of ANA might be associated with a poor outcome of such treatment.",
author = "Yasuto Yoneshima and Kentaro Tanaka and Yoshimasa Shiraishi and Kojiro Hata and Hiroyuki Watanabe and Taishi Harada and Kohei Otsubo and Eiji Iwama and Hiroyuki Inoue and Satohiro Masuda and Yoichi Nakanishi and Isamu Okamoto",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.lungcan.2019.01.014",
language = "English",
volume = "130",
pages = "5--9",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

AU - Yoneshima, Yasuto

AU - Tanaka, Kentaro

AU - Shiraishi, Yoshimasa

AU - Hata, Kojiro

AU - Watanabe, Hiroyuki

AU - Harada, Taishi

AU - Otsubo, Kohei

AU - Iwama, Eiji

AU - Inoue, Hiroyuki

AU - Masuda, Satohiro

AU - Nakanishi, Yoichi

AU - Okamoto, Isamu

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objectives: To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small cell lung cancer (NSCLC). Patients and methods: Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor. Results: Of the 83 patients analyzed, 18 (21.7%) were positive for ANA. The incidence of immune-related adverse events (irAEs) did not differ significantly between patients with ANA (6/18, 33.3%) and those negative for ANA (21/65, 32.3%), although it tended to increase as the ANA titer increased. Progression-free survival (2.9 versus 3.8 months, p = 0.03) and overall survival (11.6 versus 15.8 months, p = 0.03) were significantly shorter in patients positive for ANA than in those without ANA. Conclusion: PD-1 inhibitors can be administered safely in advanced NSCLC patients positive for ANA without obvious exacerbation of autoimmune disease, although patients with a high titer of such antibodies may warrant close monitoring. However, the presence of ANA might be associated with a poor outcome of such treatment.

AB - Objectives: To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small cell lung cancer (NSCLC). Patients and methods: Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor. Results: Of the 83 patients analyzed, 18 (21.7%) were positive for ANA. The incidence of immune-related adverse events (irAEs) did not differ significantly between patients with ANA (6/18, 33.3%) and those negative for ANA (21/65, 32.3%), although it tended to increase as the ANA titer increased. Progression-free survival (2.9 versus 3.8 months, p = 0.03) and overall survival (11.6 versus 15.8 months, p = 0.03) were significantly shorter in patients positive for ANA than in those without ANA. Conclusion: PD-1 inhibitors can be administered safely in advanced NSCLC patients positive for ANA without obvious exacerbation of autoimmune disease, although patients with a high titer of such antibodies may warrant close monitoring. However, the presence of ANA might be associated with a poor outcome of such treatment.

UR - http://www.scopus.com/inward/record.url?scp=85061030654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061030654&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2019.01.014

DO - 10.1016/j.lungcan.2019.01.014

M3 - Article

VL - 130

SP - 5

EP - 9

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -